Wego Blood Purification released its 2026 interim report. Total operating revenue was 1.758 billion yuan, down 0.36 percent from the same period last year, and net profit attributable to the parent company was 230 million yuan. Net cash inflow from operating activities was 129 million yuan, down 31.85 percent year on year. The company's latest asset-liability ratio was 14.63 percent, and gross margin was 37.88 percent, ranking 55th among comparable companies that have already disclosed results, down 3.22 percentage points from the same period last year. Latest return on equity was 3.18 percent, ranking 42nd, down 0.06 percentage points from a year earlier. Diluted earnings per share were 0.55 yuan, down 5.17 percent year on year. Total asset turnover was 0.21 times and inventory turnover was 1.30 times, both lower than the same period last year. The company had 16,400 shareholders, and the top ten shareholders held 83.04 percent of the shares.
Shandong Weigao BloodNet profit and operating cash flow declined year-on-year, with lower margins and turnover.